PolyPid Ltd. (NASDAQ:PYPD) Receives $11.67 Consensus Target Price from Brokerages

PolyPid Ltd. (NASDAQ:PYPD) has received an average recommendation of “Moderate Buy” from the five research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $11.3333.

Several analysts recently commented on the company. HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of PolyPid in a research report on Tuesday, July 21st. Craig Hallum set a $12.00 price target on PolyPid in a research report on Wednesday. Finally, Weiss Ratings upgraded PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 23rd.

Institutional Investors Weigh In On PolyPid

Several institutional investors have recently bought and sold shares of the stock. AIGH Capital Management LLC grew its position in PolyPid by 26.1% in the 4th quarter. AIGH Capital Management LLC now owns 1,342,972 shares of the company’s stock valued at $5,828,000 after buying an additional 277,844 shares in the last quarter. HighTower Advisors LLC bought a new stake in shares of PolyPid during the 4th quarter worth about $44,000. Jane Street Group LLC bought a new stake in shares of PolyPid during the 4th quarter worth about $66,000. XTX Topco Ltd lifted its stake in shares of PolyPid by 50.0% in the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock worth $142,000 after acquiring an additional 10,888 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of PolyPid in the 4th quarter worth approximately $451,000. Institutional investors and hedge funds own 26.47% of the company’s stock.

Key PolyPid News

Here are the key news stories impacting PolyPid this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating on PolyPid and maintained a $13 price target, signaling continued confidence in the stock’s longer-term potential. The firm also slightly raised its Q2 2026 EPS estimate and Q4 2026 EPS estimate, which may help support sentiment. Article Title
• Neutral Sentiment: HC Wainwright made several forecast adjustments for future years, with some estimates improving and others declining. The changes suggest analysts still see meaningful uncertainty in PolyPid’s earnings path, but not a major shift in the overall investment thesis.
• Negative Sentiment: Short interest in PolyPid (PYPD) rose sharply in July to 283,206 shares, up 235.2% from late June, with about 2.0% of shares sold short. Rising short interest can indicate growing skepticism among traders and may weigh on the stock. Article Title
• Negative Sentiment: HC Wainwright cut its FY2027, FY2028, FY2029, and FY2030 EPS estimates for PolyPid, including a sizeable reduction to FY2030 expectations. Lower long-term earnings forecasts can pressure valuation expectations, even though the firm kept its bullish rating. Article Title

PolyPid Stock Performance

NASDAQ PYPD opened at $3.90 on Wednesday. The company has a 50-day moving average price of $4.84 and a two-hundred day moving average price of $4.58. PolyPid has a 52 week low of $3.06 and a 52 week high of $5.73. The stock has a market cap of $74.41 million, a price-to-earnings ratio of -2.04 and a beta of 1.40.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.12. As a group, equities research analysts expect that PolyPid will post -0.77 earnings per share for the current fiscal year.

PolyPid Company Profile

PolyPid Ltd is a clinical?stage biotechnology company focused on polymer?based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus?Penetrating (MMP) platform, PolyPid develops long?acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer?formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.